Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:RANI 17 October 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics shares traded around $1.59 on 28 November, down from the previous close of $1.62 but still well above pre-October levels. No new press releases or SEC filings were issued today. The stock’s recent surge followed a major Chugai Pharmaceutical collaboration and $60.3 million private placement. Market cap stands near $190–200 million with roughly 97.5 million shares outstanding.
28 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics shares surged over 300% in a month, jumping to $2.20–$2.50 after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal brought $10 million upfront and extended Rani’s cash runway into 2028 with a $60.3 million financing. Analyst targets rose as high as $11. Trading volume spiked tenfold, with the stock breaking key technical levels.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani Therapeutics stock surged 330% in October, closing at $2.20 on Nov. 1 after announcing a $1.085 billion licensing deal with Chugai and positive preclinical data for its oral semaglutide pill. The company, which has no approved products or meaningful revenue, raised $60.3 million in a private placement. Analysts rate RANI a Buy, but warn of high risk due to ongoing losses and no product sales.
1 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Rani Therapeutics shares closed at $2.20 on Oct. 31, up 51.7% for the day, following a $1.09 billion collaboration deal with Chugai Pharma and a $60.3 million equity raise. Trading volume surged, with nearly 172 million shares changing hands Oct. 20. Founder Mir Imran bought 2.08 million shares Oct. 27. Wall Street analysts now rate RANI a “Strong Buy” with average price targets near $10–11.
31 October 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics shares jumped 248% to close at $1.64 on October 17, 2025, after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in a private placement, boosting its cash position. Rani will get $10 million upfront from Chugai and up to $175 million in milestones for its first oral drug program.
20 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics shares surged 248% to close at $1.64 on Oct. 17 after announcing a collaboration with Chugai Pharmaceutical worth up to $1.08 billion. The deal includes $10 million upfront and up to $175 million in milestones for the first drug. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. The company’s RaniPill technology delivers injectable drugs via oral capsules.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···

Stock Market Today

  • Palantir's Sky-High Valuation Reflects Robust AI Optimism, Heightening Risk
    April 9, 2026, 3:40 PM EDT. Palantir Technologies (PLTR) is trading at valuations signaling very high investor expectations, with trailing and forward price-to-earnings multiples exceeding 238 and 95 times respectively. Its price-to-sales ratios surpass 80 and 42 times, far above sector peers like Snowflake (below 11 and 9 times) and Datadog, underscoring a steep premium on Palantir's AI and data analytics leadership. Such rich valuation multiples imply the market forecasts rapid revenue growth and improved profits, but also leave little margin for error. Any growth misses or margin setbacks could prompt sharp share price declines. Despite strong demand for AI and increasing commercial clientele, investors are advised caution given the stretched valuation compared to comparable tech companies.

Latest article

Mortgage Rates Today: 30-Year Fixed Falls to 6.37% After Five-Week Climb (Freddie Mac)

Mortgage Rates Today: 30-Year Fixed Falls to 6.37% After Five-Week Climb (Freddie Mac)

9 April 2026
The average 30-year fixed mortgage rate fell to 6.37% from 6.46%, Freddie Mac said Thursday. Purchase mortgage applications rose 1% last week but remained 7% lower than a year ago, according to the Mortgage Bankers Association. Refinance activity dropped 3%. Mortgage News Daily’s index showed the 30-year fixed at 6.38%, with the 10-year Treasury near 4.27%.
Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

9 April 2026
Bitcoin traded near $72,000 Thursday, up 0.3%, after earlier slipping on renewed Middle East tensions. U.S. spot bitcoin ETFs saw $471.4 million in inflows April 6 but $93.9 million in outflows April 8, as Morgan Stanley’s new MSBT fund debuted with $30.6 million. Ether fell 0.9% to $2,210.56. Bitcoin remains 43% below its October 2025 record high.
Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

9 April 2026
Spot silver jumped 2.9% to $76.24 an ounce Thursday, extending gains after a U.S.-Iran ceasefire and a weaker dollar. Gold rose 1.63% to $4,793.07. Analysts warned the truce remains fragile, with markets watching for March U.S. inflation data due Friday. Oil fell below $100 but tensions persisted in the Middle East.
Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

9 April 2026
Spot gold rose 1.6% to $4,789.67 an ounce by 1:30 p.m. ET Thursday as the U.S. dollar weakened and Treasury yields slipped. U.S. gold futures settled 0.9% higher at $4,818.00. Traders watched a fragile ceasefire between Washington and Tehran and awaited Friday’s U.S. inflation data. March saw gold’s steepest monthly drop since 2008, according to China’s central bank.
Go toTop